查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863429

细胞和基因治疗生物製造CDMO市场按服务类型、治疗方法、技术、应用、规模、最终用户和製程阶段划分－全球预测，2025-2032年

Cell & Gene Therapy Biomanufacturing CDMO Market by Service Type, Therapy Type, Technology, Application, Scale, End User, Process Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞和基因治疗生物製造 CDMO 市场将成长至 43.7541 亿美元，复合年增长率为 31.63%。

主要市场统计数据
基准年 2024 4.8547亿美元
预计年份：2025年 6.4087亿美元
预测年份：2032年 43.7541亿美元
复合年增长率 (%) 31.63%

相关人员明确指出，大规模生产先进治疗方法，必须协调製造能力、监管准备和商业计划，这是策略上的当务之急。

生物学与製造技术的融合正在重塑先进治疗方法从概念到临床的转化路径。基因编辑、载体工程和细胞处理领域的最新突破提升了治疗潜力，同时也提高了生产製造的技术和监管门槛。随着关注点从实验室规模的创新转向稳健、可重复的生产，各机构必须重新思考伙伴关係、设施策略和产能投资，以维持临床应用效率并确保产品品质。

技术、商业和监管方面的变革正迫使合约研发生产机构（CDMO）和开发商寻求整合平台策略，以获得可持续的竞争优势。

细胞和基因疗法生物製造领域正经历多重融合的变革，这些变革正在重新定义产品的开发、生产和交付方式。载体设计、非病毒递送方法和封闭式系统处理的技术进步提高了产品的稳健性并降低了污染风险，而分析技术和製程表征方面的同步进步则使得对产品特性的控制更加精准。这些改进促使申办方和服务供应商将平台的稳健性和工艺的可重复性置于单纯的生产能力之上。

评估2025年关税变化将如何加剧供应链风险，并鼓励先进治疗药物製造领域的采购多元化和策略性回流

影响关税和贸易的政策决策会对先进治疗方法系统产生连锁反应，改变成本、进度和供应商关係。 2025年推出的最新关税政策，为组件、一次性耗材以及某些通常透过复杂的全球供应链进口的原材料带来了新的贸易摩擦。这迫使各机构重新评估对供应商的依赖程度、定价策略和库存政策，以维持专案进度和分析效率。

依服务类型、技术、治疗方法和流程阶段进行详细的細項分析，区分能力、监管要求和投资重点。

细緻的細項分析揭示了不同服务类型、治疗方法、技术选择、应用、规模、最终用户和製程阶段的需求差异，从而在整个生态系统中形成了独特的机会和风险。对服务类型的检验表明，分析服务、临床生产、商业生产和製程开发提供者面临着不同的需求驱动因素：分析服务越来越需要平台化的检测方法和可比性方面的专业知识；临床生产侧重于快速放大生产规模和CMC製备；商业生产需要可持续的产量和成本控制；而製程开发则弥合了药物发现和可重复生产之间的差距。

区域监管成熟度、製造能力和供应链趋势如何重塑全球市场的伙伴关係模式和投资决策

区域趋势正在以不同的方式影响製造商、赞助商和服务供应商的策略重点。在美洲，成熟的製造生态系统和完善的法规结构支援计画快速推进至临床营运阶段。同时，北美供应链和契约製造网路集中了病毒和非病毒平台的研发能力。这种环境有利于能够快速适应并扩展规模以满足严格监管要求的伙伴关係，但也加剧了对人才和专业能力的竞争。

竞争格局概述：规模、专业化和策略联盟如何决定供应商差异化和长期客户维繫

先进治疗方法生产生态系统的竞争格局复杂多样，涵盖了大型传统合约研发生产机构 (CDMO)、专业载体和细胞疗法服务供应商，以及垂直整合的研发生产公司。成熟的契约製造凭藉其规模优势、丰富的监管经验和全球覆盖范围，展现出卓越的价值，尤其对于即将实现商业化供应的项目而言。同时，专业服务提供者和新兴企业则凭藉在特定载体类型、新型给药方式或客製化製程开发服务方面的深厚技术专长脱颖而出，提供高触感的服务，从而加速早期专案并降低转换障碍的风险。

为相关人员提供切实可行的策略性倡议，以降低转化风险，并为先进治疗方法建立稳健、可扩展的生产管道。

领导者应采取果断行动，弥合科学创新与可製造性之间的鸿沟，优先考虑能够保障专案进度和病患用药机会的投资和合作。首先，在专案生命週期的早期阶段就应协调製程开发和分析，确保将规模化生产考量和产品发布标准纳入产品设计决策。这将有助于制定清晰的技术转移蓝图，降低下游製程风险，并加快达到监管合规要求的速度。

一种实用且可复製的研究途径，结合访谈、技术文献和监管指南，检验营运和策略製造方面的洞见。

本研究综合运用横断面分析方法，结合一手和二手研究，对细胞和基因治疗生物製造领域的生产趋势、营运挑战和策略应对措施进行系统性阐述。一级资讯来源包括对申办公司和服务供应商的製造、CMC（化学、生产和品管）以及监管部门高级领导进行的结构化访谈。此外，还与製程开发科学家和供应链经理进行了技术交流，以了解营运方面的限制和应对措施。这些定性访谈旨在揭示实际决策标准，并协调临床开发需求与商业性生产要求之间的差异。

从整体角度审视製造策略、监管准备和供应链韧性之间的联繫，将其视为先进治疗方法长期成功的核心决定因素。

对技术、营运和策略因素的综合分析揭示了正在变革时期中的製造业生态系统。虽然科学创新加速了治疗潜力的发挥，但对工艺科学、供应链韧性和一体化伙伴关係关係的重点投资对于确保潜力的实现至关重要。那些从早期研发阶段就协调可扩展製造方法、实现采购和地理风险多元化并建立健全的分析和品质体系的组织，将更有利于在治疗方法走向广泛临床应用的过程中，保持专案进展势头并确保患者获得治疗。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合自动化封闭式反应器系统，以提高细胞疗法的可扩展性并降低污染风险
  • 在细胞和基因治疗生产中应用数位双胞胎建模和人工智慧驱动的过程分析，实现生物製程的即时优化
  • 扩大同种异体细胞疗法契约製造，以满足不断增长的全球商业需求
  • 引入一次性感测器技术，用于病毒载体生产中关键品质属性的连续监测和控制
  • CDMO与学术研究机构进行策略合作，加速新型基因编辑平台符合cGMP规范
  • 开发用于分散式细胞疗法管理和社区医院生产的模组化填充密封解决方案
  • 监管协调倡议旨在全球统一CAR-T和基因治疗产品的疗效评估标准
  • 引入可扩展的质体DNA供应链，以支援下一代病毒载体生产的快速规模化。
  • 上游连续培养製程的进步可提高病毒载体产量并降低生产成本
  • 在细胞和基因治疗CDMO业务中实施永续性倡议，例如绿色溶剂製程和可再生能源的使用。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 细胞和基因治疗生物製造CDMO市场按服务类型划分

  • 分析服务
  • 临床生产
  • 商业生产
  • 製程开发

9. 按治疗方法类型分類的细胞和基因治疗生物製造CDMO市场

  • 细胞疗法
    • 同种异体移植
    • 自体移植
  • 基因治疗

10. 细胞和基因治疗生物製造CDMO市场（依技术划分）

  • 非病毒载体
    • 电穿孔
    • 脂质奈米颗粒
  • 病毒载体
    • AAV
    • 腺病毒
    • 慢病毒
    • 逆转录病毒

第十一章：细胞与基因治疗生物製造CDMO市场（依应用领域划分）

  • 循环系统
  • 神经病学
  • 肿瘤学
  • 罕见疾病

第十二章：细胞与基因治疗生物製造CDMO市场规模

  • 临床量表
  • 商业规模
  • 临床前规模

第十三章：细胞与基因治疗生物製造CDMO市场（依最终用户划分）

  • 生物製药公司
  • 受託研究机构
  • 研究所

14. 细胞与基因治疗生物製造CDMO市场依製程阶段划分

  • 下游工艺
  • 上游工艺

15. 细胞和基因治疗生物製造CDMO市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：细胞和基因治疗生物製造CDMO市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：各国细胞与基因治疗生物製造CDMO市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争情势

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Lonza Group AG
    • Catalent, Inc.
    • Thermo Fisher Scientific, Inc.
    • Fujifilm Diosynth BIoTechnologies USA, Inc.
    • WuXi AppTec Co., Ltd.
    • Charles River Laboratories International, Inc.
    • AGC Biologics, Inc.
    • Samsung Biologics Co., Ltd.
    • Merck KGaA
    • Recipharm AB
Product Code: MRR-5C6F41F5AF94

The Cell & Gene Therapy Biomanufacturing CDMO Market is projected to grow by USD 4,375.41 million at a CAGR of 31.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 485.47 million
Estimated Year [2025] USD 640.87 million
Forecast Year [2032] USD 4,375.41 million
CAGR (%) 31.63%

Framing the strategic urgency for stakeholders to align manufacturing capability, regulatory readiness, and commercial planning for advanced therapies at scale

The intersection of biology and manufacturing is reshaping how advanced therapies move from concept to clinic. Recent breakthroughs in gene editing, vector engineering, and cell processing have elevated therapeutic promise while simultaneously raising the technical and regulatory bar for manufacturing. As attention shifts from lab-scale innovation to robust, reproducible production, organizations must rethink partnerships, facility strategies, and capability investment to sustain clinical throughput and ensure product quality.

These dynamics demand that stakeholders-biopharmaceutical developers, contract manufacturers, investors, and regulators-adopt a strategic lens on capacity, technology fit, and supply chain resiliency. Critical decisions made today about process platforms, vector technologies, and outsourced relationships will determine not only the speed to first-in-human studies but also the ability to scale to broader patient populations. Consequently, executives must balance near-term program needs with long-term platform viability in a landscape where scientific complexity and commercial expectations evolve in parallel.

This summary frames the operational, strategic, and commercial pressures shaping cell and gene therapy biomanufacturing and highlights where targeted action can reduce risk and create value across development and manufacturing lifecycles.

How converging technological, commercial, and regulatory shifts are forcing CDMOs and developers to pursue integrated platform strategies for durable competitive advantage

The biomanufacturing landscape for cell and gene therapies is undergoing several converging shifts that are redefining how products are developed, manufactured, and delivered. Technological progress in vector design, non-viral delivery modalities, and closed-system processing is increasing robustness and reducing contamination risk, while parallel advances in analytics and process characterization are enabling deeper control over product attributes. These improvements are prompting sponsors and service providers to prioritize platform resilience and process reproducibility as much as raw capacity.

Concurrently, commercialization pressures are reshaping business models. The need to de-risk supply and accelerate time to clinic has driven more developers to partner with specialized manufacturing organizations, but those partnerships are evolving beyond transactional capacity provision toward integrated service models that encompass process development, regulatory support, and lifecycle management. This shift is accelerating demand for vertically integrated capabilities that can take a program from vector or cell process definition through clinical and commercial manufacturing under a harmonized quality framework.

Finally, regulatory and reimbursement environments are maturing in many jurisdictions, emphasizing consistent product quality, post-market evidence generation, and supply chain transparency. As a result, successful players are those investing in cross-functional integration-uniting scientific innovation with manufacturing science, regulatory strategy, and commercial planning-to ensure therapies can transition smoothly from proof of concept to sustainable patient access.

Assessing how 2025 tariff shifts in the United States are amplifying supply chain risks, prompting sourcing diversification and strategic onshoring in advanced therapy manufacturing

Policy decisions affecting tariffs and trade can have ripple effects across the advanced therapy ecosystem, altering costs, timelines, and supplier relationships. Recent tariff developments in the United States introduced in 2025 have created new transactional friction for components, single-use consumables, and certain raw materials frequently imported through complex global supply chains. This has led organizations to reassess supplier dependencies, pricing strategies, and inventory policies to preserve program schedules and analytical throughput.

Manufacturers and service providers have responded by diversifying sourcing, qualifying alternate suppliers, and in some cases accelerating onshoring of critical inputs to mitigate exposure. For many stakeholders, the cumulative effect is not just an incremental cost increase but a strategic prompt to re-evaluate the end-to-end supply chain. Decisions about where to locate production capacity or whether to maintain buffer inventories are now being made with an eye toward tariff sensitivity, supplier concentration, and logistical complexity.

Moreover, the policy environment has underscored the value of contractual flexibility and regional redundancy. Sponsors that had pre-existing multi-region supply strategies found it easier to absorb transactional shocks, while those with heavily concentrated supplier networks faced longer lead times to secure alternates. Ultimately, tariff-related pressures are accelerating conversations about supply chain resilience, qualifying secondary sources, and embedding contingency planning into program timelines and vendor selection criteria.

Detailed segmentation analysis that differentiates capability, regulatory needs, and investment priorities across service types, technologies, therapy modalities, and process stages

A nuanced segmentation lens reveals how needs diverge across service types, therapy modalities, technology choices, applications, scales, end users, and process stages, creating distinct opportunity and risk profiles across the ecosystem. When examining service type, providers offering analytical services, clinical manufacturing, commercial manufacturing, and process development are experiencing different demand drivers: analytical services increasingly require platformized assays and comparability expertise, clinical manufacturing focuses on rapid scale-up and CMC readiness, commercial manufacturing demands sustained throughput and cost control, and process development bridges discovery and reproducible manufacturing.

Therapy type further differentiates strategy and operations. Cell therapy and gene therapy programs have divergent material flows and regulatory touchpoints, and within cell therapy, allogeneic models emphasize donor sourcing, banking, and immunogenicity control, while autologous models concentrate on individualized logistics and rapid turnaround. Platform technology influences both cost structure and operational complexity; non-viral vectors such as electroporation and lipid nanoparticles offer alternative manufacturing pathways with distinct analytical packages, whereas viral vector platforms include AAV, adenovirus, lentivirus, and retrovirus-each with specific production, purification, and potency challenges that shape facility design and regulatory dossiers.

Application and therapeutic area impact clinical development and manufacturing priorities. Development for cardiovascular, neurology, oncology, and rare diseases requires tailored potency assays, varying dosing paradigms, and different patient recruitment dynamics that affect batch sizes and release testing strategies. Scale considerations-clinical scale, commercial scale, and preclinical scale-translate directly into capital planning and technology selection, since processes that are fit-for-purpose at one scale may not transition economically to another without significant redevelopment. End users such as biopharmaceutical companies, contract research organizations, and research institutions bring different expectations around service level, documentation, and flexibility, influencing how providers design contracting models and capacity commitments.

Finally, process stage segmentation into upstream and downstream activities highlights where investment and expertise concentrate. Upstream operations drive productivity through cell line or vector production efficiencies, while downstream operations determine purity, yield, and formulation stability. Integrating insights across these segmentation dimensions enables stakeholders to align capabilities, prioritize investments, and select partners that match both program-specific technical needs and broader commercialization objectives.

How regional regulatory maturity, manufacturing capacity, and supply chain dynamics are reshaping partnership models and investment decisions across global markets

Regional dynamics shape strategic priorities for manufacturers, sponsors, and service providers in distinct ways. In the Americas, mature manufacturing ecosystems and established regulatory frameworks support rapid program transitions to clinical operations, while North American supply chains and contract manufacturing networks have concentrated capabilities in both viral and non-viral platforms. This environment favors partnerships that can quickly scale and align with stringent regulatory expectations, but it also intensifies competition for qualified talent and specialized capacity.

Across Europe, the Middle East & Africa, diversity in regulatory approaches and infrastructure maturity creates mixed incentives. European markets emphasize harmonized regulatory alignment and stringent quality systems, while several Middle Eastern and African jurisdictions are in earlier stages of capacity building. These differences encourage cross-border collaborations, distributed manufacturing strategies, and investment in regional centers of excellence that can support local clinical programs and provide redundancy for global operations.

In the Asia-Pacific region, rapid expansion of biotech ecosystems, growing domestic biopharma investment, and evolving regulatory pathways are driving significant capability growth. Local suppliers and CDMOs are increasingly competitive on cost and are investing in technical depth across viral vectors and non-viral modalities. Consequently, many global sponsors are balancing near-term cost considerations with long-term risk management by combining local partnerships for certain activities with established partners in other regions to ensure global regulatory alignment and continuity of supply.

Competitive landscape overview highlighting how scale, specialization, and strategic partnerships determine provider differentiation and long-term client retention

Competitors in the advanced therapy manufacturing ecosystem now span legacy large-scale CDMOs, specialized vector and cell therapy service providers, and vertically integrated developer-manufacturers, creating a diverse competitive landscape. Established contract manufacturers bring scale, regulatory experience, and global footprint, which is particularly valuable for programs approaching commercial supply needs. At the same time, specialized providers and emerging firms differentiate through deep technical expertise in specific vector types, novel delivery modalities, or bespoke process development services, offering high-touch capabilities that can accelerate early-stage programs and de-risk translational hurdles.

Strategic partnerships and M&A activity have been common as organizations seek to close capability gaps and secure capacity. Collaborations between technology licensors, equipment manufacturers, and service providers are enabling faster adoption of automation, single-use technologies, and high-throughput analytics. Additionally, academic spinouts and research institutions continue to be critical sources of innovation, feeding new modalities and process approaches into the commercial supply chain. The competitive imperative is to blend scientific differentiation with operational excellence: firms that can demonstrate reproducible processes, robust quality systems, and flexible capacity will be best positioned to capture long-term customer relationships.

Actionable strategic moves for stakeholders to reduce translational risk and build resilient, scalable manufacturing pathways for advanced therapies

Leaders must act decisively to bridge scientific innovation and manufacturability, prioritizing investments and partnerships that protect program timelines and patient access. First, align process development and analytics early in the program lifecycle to ensure that scale-up considerations and release criteria are embedded into product design decisions. This reduces downstream risk and shortens the path to regulatory readiness by creating a clear technical transfer roadmap.

Second, diversify supplier and component sourcing by qualifying secondary suppliers and exploring regional alternatives for critical consumables. Embedding contingency planning into contracts and procurement strategies minimizes disruption from trade policy shifts or single-source failures. Third, invest in platform technologies and automation that increase reproducibility while lowering per-batch variability; standardized unit operations and modular facility designs can accelerate scale-up and reduce the cost and time of facility commissioning. Fourth, pursue integrated partnership models where process development, clinical manufacturing, and regulatory support are closely coordinated to maintain continuity and accountability across transitions. This approach reduces knowledge loss during tech transfer and improves overall program velocity. Finally, commit to workforce development and cross-functional training to ensure teams can execute complex programs end-to-end, combining technical proficiency with regulatory and quality-system literacy to maintain compliance under evolving regulatory expectations.

Practical and reproducible research approach combining interviews, technical literature, and regulatory guidance to validate operational and strategic manufacturing insights

This research synthesis draws on a multi-channel analysis of primary and secondary inputs to create a coherent view of manufacturing trends, operational challenges, and strategic responses within cell and gene therapy biomanufacturing. Primary inputs include structured interviews with senior manufacturing, CMC, and regulatory leaders across sponsor and service-provider organizations, supplemented by technical dialogues with process development scientists and supply chain managers to understand operational constraints and mitigation strategies. These qualitative engagements were designed to surface real-world decision criteria and to reconcile differences between clinical development imperatives and commercial manufacturing requirements.

Secondary inputs comprised peer-reviewed literature, regulatory guidances, technical white papers, and public disclosures from product developers and service providers to validate technology trends and facility design patterns. Cross-validation techniques were used to triangulate insights from interviews with documented process architectures and regulatory expectations. Attention was paid to reproducibility of technical claims, and areas of high uncertainty are explicitly noted where divergent industry practices remain. The combined approach emphasizes practical relevance, privileging insights that can inform near-term operational planning and strategic partnerships while documenting assumptions and limitations that readers should consider when applying findings to specific programs.

Concluding synthesis that links manufacturing strategy, regulatory readiness, and supply chain resilience as the core determinants of long-term success for advanced therapies

Synthesis of the technical, operational, and strategic threads reveals a manufacturing ecosystem in transition: scientific innovation is accelerating therapeutic possibilities, but realizing those possibilities reliably requires focused investments in process science, supply chain resilience, and integrated partnerships. Organizations that harmonize early-stage development with scalable manufacturing practices, diversify sourcing and regional exposure, and commit to robust analytics and quality systems will be better positioned to sustain program momentum and patient access as therapies move toward broader clinical adoption.

Looking ahead, the interplay of technology choices, regulatory expectations, and commercial realities will continue to shape which programs can be advanced sustainably. Stakeholders that view manufacturing strategy as an enabler of clinical and commercial success-rather than a downstream constraint-will capture disproportionate value. The challenge is to translate technical ingenuity into reproducible, regulatory-ready processes at scale, and the most successful organizations will be those that build integrated roadmaps linking process development, regulatory planning, and supply chain design to deliver therapies reliably to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of automated closed system bioreactors to enhance cell therapy scalability and reduce contamination risk
  • 5.2. Adoption of digital twin modeling and AI-driven process analytics for real-time bioprocess optimization in cell and gene therapy manufacturing
  • 5.3. Expansion of allogeneic cell therapy contract manufacturing capabilities to meet increasing global commercial demand
  • 5.4. Implementation of single-use sensor technologies for continuous monitoring and control of critical quality attributes in viral vector production
  • 5.5. Strategic partnerships between CDMOs and academic labs to accelerate cGMP translation of novel gene editing platforms
  • 5.6. Development of modular fill-finish solutions for decentralized cell therapy administration and local hospital-based manufacturing
  • 5.7. Regulatory alignment efforts toward harmonized global standards for potency assays in CAR-T and gene therapy products
  • 5.8. Adoption of scalable plasmid DNA supply chains to support rapid scale-up of next-generation viral vector production
  • 5.9. Advances in upstream perfusion culture processes to increase yields of viral vectors and reduce production costs
  • 5.10. Incorporation of sustainability initiatives such as green solvent processes and renewable energy use in cell and gene therapy CDMO operations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Biomanufacturing CDMO Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Clinical Manufacturing
  • 8.3. Commercial Manufacturing
  • 8.4. Process Development

9. Cell & Gene Therapy Biomanufacturing CDMO Market, by Therapy Type

  • 9.1. Cell Therapy
    • 9.1.1. Allogeneic
    • 9.1.2. Autologous
  • 9.2. Gene Therapy

10. Cell & Gene Therapy Biomanufacturing CDMO Market, by Technology

  • 10.1. Non-Viral Vector
    • 10.1.1. Electroporation
    • 10.1.2. Lipid Nanoparticles
  • 10.2. Viral Vector
    • 10.2.1. Aav
    • 10.2.2. Adenovirus
    • 10.2.3. Lentivirus
    • 10.2.4. Retrovirus

11. Cell & Gene Therapy Biomanufacturing CDMO Market, by Application

  • 11.1. Cardiovascular
  • 11.2. Neurology
  • 11.3. Oncology
  • 11.4. Rare Diseases

12. Cell & Gene Therapy Biomanufacturing CDMO Market, by Scale

  • 12.1. Clinical Scale
  • 12.2. Commercial Scale
  • 12.3. Preclinical Scale

13. Cell & Gene Therapy Biomanufacturing CDMO Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Contract Research Organizations
  • 13.3. Research Institutions

14. Cell & Gene Therapy Biomanufacturing CDMO Market, by Process Stage

  • 14.1. Downstream
  • 14.2. Upstream

15. Cell & Gene Therapy Biomanufacturing CDMO Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Cell & Gene Therapy Biomanufacturing CDMO Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Cell & Gene Therapy Biomanufacturing CDMO Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Lonza Group AG
    • 18.3.2. Catalent, Inc.
    • 18.3.3. Thermo Fisher Scientific, Inc.
    • 18.3.4. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • 18.3.5. WuXi AppTec Co., Ltd.
    • 18.3.6. Charles River Laboratories International, Inc.
    • 18.3.7. AGC Biologics, Inc.
    • 18.3.8. Samsung Biologics Co., Ltd.
    • 18.3.9. Merck KGaA
    • 18.3.10. Recipharm AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY AAV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY LENTIVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RETROVIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PRECLINICAL SCALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY DOWNSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SCALE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY PROCESS STAGE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY BIOMANUFACTURING CDMO MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)

TABL